Business
Natera Adds to Organ Health Medical Affairs Leadership Team
Sangeeta Bhorade, M.D., appointed as head of organ health medical affairs AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global
About this update from Natera, Inc.
[{"type":"text","content":"Sangeeta Bhorade, M.D., appointed as head of organ health medical affairs\nAUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the hiring of Sangeeta Bhorade, M.D., as vice president of organ health medical affairs. Dr. Bhorade joins Natera as the latest addition amongst other recent notable medical leadership hires, including Michael Olymbios, M.D., medical director of heart transplantation, and David Ross, M.D., medical director of lung transplantation.\n\n \n \n \n \n \n \n\n \nDr. Bhorade brings more than 27 years of experience as an academic physician. She previously served as the founding medical director at the University of Chicago lung transplant program, and later joined as the founding medical director for the Northwestern University lung transplant program, which developed into a premium program in the region under her leadership. She is a graduate of the University of Chicago, where she also completed her residency and fellowship in pulmonary and critical care. Prior to joining Natera, Dr. Bhorade served as medical director at Veracyte, where she was instrumental in building a novel lung cancer diagnostic test and furthered the management of lung nodules. \n\"As a highly regarded leader in the transplantation field, Sangeeta brings a wealth of experience and an innovative vision to improve patient care for organ transplant recipients,\" said Bernie Tobin, general manager, organ health at Natera. \"With over 80 papers published to date, she has a passion for innovation and will provide Natera with her invaluable clinical expertise during this exciting growth period in our organ health efforts.\" \nDr. Olymbios has extensive research experience in redefining the standard for the detection and definition of rejection in heart transplant. Prior to joining Natera in 2020, he was at the Heart Transplant Program of Cedars-Sinai Medical Center in Los Angeles. Dr. Olymbios co-authored the international guidelines for the management of antibodies in heart transplantation as part of the International Society for Heart and Lung Transplantation (ISHLT). He was also part of the American Society of Transplantation work group on the role of frailty in solid organ transplantation. Dr. Olymbios attended medical school in the United Kingdom at Imperial Col...